Business Description
Curasight AS
ISIN : DK0061295797
Share Class Description:
XSAT:CURAS: Ordinary SharesCompare
Compare
Traded in other countries / regions
CURAS.Sweden IPO Date
2020-10-08Description
Curasight AS is a clinical-stage biotech company committed to improving both diagnosis and the treatment of certain types of cancer. The company is focused on exploiting Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.81 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -70.8 | |||||
| 3-Year EPS without NRI Growth Rate | -60.4 | |||||
| 3-Year FCF Growth Rate | -31.2 | |||||
| 3-Year Book Growth Rate | -23 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 65.62 | |||||
| 9-Day RSI | 56.95 | |||||
| 14-Day RSI | 51.38 | |||||
| 6-1 Month Momentum % | -44.17 | |||||
| 12-1 Month Momentum % | -62.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.22 | |||||
| Quick Ratio | 4.22 | |||||
| Cash Ratio | 2.73 | |||||
| Days Payable | 32.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -58.45 | |||||
| ROA % | -54.2 | |||||
| ROIC % | -194.79 | |||||
| ROC (Joel Greenblatt) % | -2816.8 | |||||
| ROCE % | -60.37 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 6.52 | |||||
| Price-to-Tangible-Book | 8.66 | |||||
| EV-to-EBIT | -6.84 | |||||
| EV-to-EBITDA | -6.92 | |||||
| EV-to-FCF | -5.52 | |||||
| Price-to-Net-Current-Asset-Value | 8.66 | |||||
| Price-to-Net-Cash | 16.09 | |||||
| Earnings Yield (Greenblatt) % | -14.62 | |||||
| FCF Yield % | -14.57 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Curasight AS Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -1.318 | ||
| Beta | 0 | ||
| Volatility % | 102.56 | ||
| 14-Day RSI | 51.38 | ||
| 14-Day ATR (kr) | 0.722329 | ||
| 20-Day SMA (kr) | 9.9815 | ||
| 12-1 Month Momentum % | -62.78 | ||
| 52-Week Range (kr) | 8.16 - 27.4 | ||
| Shares Outstanding (Mil) | 19.89 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Curasight AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Curasight AS Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Curasight AS Frequently Asked Questions
What is Curasight AS(XSAT:CURAS)'s stock price today?
The current price of XSAT:CURAS is kr10.30. The 52 week high of XSAT:CURAS is kr27.40 and 52 week low is kr8.16.
When is next earnings date of Curasight AS(XSAT:CURAS)?
The next earnings date of Curasight AS(XSAT:CURAS) is 2024-05-23.
Does Curasight AS(XSAT:CURAS) pay dividends? If so, how much?
Curasight AS(XSAT:CURAS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers